---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-216735"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2026-05-11T20:05:17+00:00"
generated_at: "2026-05-11T22:53:04.972581+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Enanta Q2 FY2026 net loss narrows to $13.1M; Phase 1 trial started for EDP-978

## Summary
- Revenue $17.2M from AbbVie royalties (up from $14.9M YoY); net loss $13.1M ($0.45/share) vs $22.6M loss YoY.
- Cash $227M; runway into fiscal 2029; R&D spend $19.4M (down from $28.1M due to lower RSV trial costs).
- Phase 1 dosing initiated for oral KIT inhibitor EDP-978; topline data expected Q4 2026.
- Zelicapavir pivotal study enabling with FDA; update planned in Q2 2026; exploring BD opportunities.
- Litigation: Federal Circuit oral arguments vs Pfizer; decision by Sept 2026; UPC hearing Sept 29.

## SEC filing metadata
- accession: 0001193125-26-216735
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2026-05-11T20:05:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000119312526216735/0001193125-26-216735-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000119312526216735/enta-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-216735
- JSON: https://secwatch.observer/filing/0001193125-26-216735.json
- Plain text: https://secwatch.observer/filing/0001193125-26-216735.txt

## Key facts
- Earnings Releases
  ENANTA PHARMACEUTICALS INC reported fiscal second quarter ended March 31, 2026 results: revenue $17.2 million, net income Net loss ... $13.1 million, EPS loss of $0.45 per diluted common share.
  - Period: fiscal second quarter ended March 31, 2026
  - Revenue: $17.2 million
  - Net income: Net loss ... $13.1 million
  - EPS: loss of $0.45 per diluted common share
  - Result: reported results
  source text: multiple value-driving milestones over the coming year.” Fiscal Second Quarter Ended March 31, 2026 Financial Results Total revenue for the three months ended March 31, 2026 was $17.2 million and consisted of royalty revenue from worldwide net sales of MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir), AbbVie’s treatment for hepatitis C virus, compared to $14.9 million for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1177648/000119312526216735/0001193125-26-216735-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.